Green Cross Health Ltd

Green Cross Health Ltd maintains a debt-to-equity ratio of 0.81, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium risk, with a current ratio of 0.97, suggesting limited short-term liquidity cushion. Free cash flow of NZD 27.78 million supports operational flexibility, though capital expenditures of NZD 5.84 million reflect ongoing investment in infrastructure. Profitability metrics show a return on equity of 9.59% and a return on assets of 4.14%, both below the industry median for Drug Retailers. The operating margin of 7.4% (NZD 38.72 million operating income on NZD 523.76 million revenue) lags behind the sector average, indicating potential inefficiencies in cost management or pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation exposes Green Cross Health Ltd to localized demand shocks and regulatory risks. No material international revenue is reported, suggesting a domestic New Zealand focus. Revenue growth has been modest, with actual revenue of NZD 568.53 million trailing the NZD 523.76 million reported in the latest financial snapshot. Analysts project continued low-growth dynamics, with no material acceleration in revenue or margin expansion expected in the next fiscal year. Risk factors include a negative net cash position after subtracting total debt, which elevates liquidity risk. Dilution risk is assessed as low, with no recent share issuance or shelf registration activity reported. However, the company's NZD 135.17 million in long-term debt could constrain financial flexibility during periods of economic stress. Recent filings and transcripts show no material changes in strategic direction or capital structure. The company remains focused on its core drug retailing operations, with no disclosed M&A activity or new market entry plans. No material regulatory or litigation risks are highlighted in the latest disclosures.